Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACH 0144471 proof-of-mechanism study in C3 glomerulopathy or idiopathic IC-MPGN
NL-OMON46833Phase 2Active, not recruiting
- Sponsor
- Achillion Pharmaceuticals
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of danicopan in Complement 3 glomerulopathy (C3G) and Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) (2 arms), sponsored by Achillion Pharmaceuticals. Primary endpoint: Increase in C3 levels relative to baseline. Started Sep 2018; status: active, not recruiting.
02
Drugs
danicopan
03
Conditions
Complement 3 glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Beyond the preview
Go deeper on NL-OMON46833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46833.